The most valuable finding is that compared with various biomarkers or volumetric methods, tumor hypoxia remained a major cause of treatment failure in patients with p16-negative PCs because GLUT1, VEGF, and HIF-1α were found to be associated with inferior outcomes. This evidence concerns the gene VEGFA and neoplasm.